

**Remarks**

Applicants have added new claim 19. Support for the added claim is found in the specification and claims as filed.

Support, for example, relating to a method of treating an allergic response to an antigen or allergy related disorder during antigen specific immunotherapy of a subject are found, for example, at: page 41 lines 15-28.

Support for administering to the subject an amount of a first composition comprising a 5'CpG3' immunostimulatory oligonucleotide that inhibits the allergic response in the subject is found on page 8 lines 14-16 and page 41 lines 15-28. The 5'CpG3' immunostimulatory oligonucleotide is described throughout the specification e.g., p. 14. The 5'CpG3' immunostimulatory oligonucleotide is a compound that decreases the activity of IgE (page 41, lines 23-26).

Support for a second composition comprising an antigen is found, for example, at: page 8 lines 14-16 (allergens), page 12 (list of allergens), and page 41 lines 26-28.

Support for an amount sufficient to modulate the immune response to the antigen is found on page 41 lines 15-28 which describe reduction in IgE specific for an antigen/allergen.

Applicants have added claims corresponding to U.S. published patent application US 2003/0064064 A1 (Dina), serial no. 10/214,288, filed August 6, 2002 and published on April 3, 2003. The present claims are filed to meet the requirements of presenting claims of patentably interfering scope within one year of publication of claims in US Patent Application, in this case U.S. published patent application US 2003/0064064 A1.

Respectfully submitted,



Helen C. Lockhart, Reg. No. 39,248  
WOLF, GREENFIELD & SACKS, P.C.  
Federal Reserve Plaza  
600 Atlantic Avenue  
Boston, Massachusetts 02210  
Tel.: (617) 720-3500

Docket No.: C1039.70048US02

Date: April 2, 2004